2025沙利文新投资大会——生命科学新投资高峰论坛议程公布

The 19th Frost & Sullivan Global Growth, Innovation and Leadership Summit and the 4th New Investment Conference (hereinafter referred to as the 2025 Frost & Sullivan New Investment Conference), hosted by Frost & Sullivan (Frost & Sullivan, abbreviated as: F&S), a globally leading growth consulting firm, will grandly kick off in Shanghai on August 27-28, 2025. During the conference, a new investment summit forum on life sciences will be launched with great momentum. This forum will bring together industry leaders, biopharmaceutical companies, medical device companies, investment institutions and professional service providers. With the theme of "Strengthening Foundations Internally and Stabilizing Amidst Waves", it focuses on cutting-edge trends, innovative technologies and globalization development strategies in the field of life sciences, aiming to promote industrial development and global cooperation.

Host CityChina · Shanghai

VenueAugust 28, 2025

Forum size:500+

Forum formatOffline + Online Live Streaming

Sponsor:Frost & Sullivan

1.Forum schedule framework

August 28

9:00 - 17:40	New Investment Summit Forum in Life Sciences (Parallel Session) —— Biopharmaceutical Session
9:00 - 17:20	New Investment Summit Forum in Life Sciences (Parallel Session) —— Medical Devices

2,Forum highlights

New Investment Summit Forum in Life Sciences (Parallel Session) —— Biopharmaceutical Session

August 28th, all day

Break the stalemate and lead the future with intelligence

After undergoing the dual tests of the capital winter and industrial restructuring, China's biopharmaceutical industry is using innovation as its spear and globalization as its shield to initiate a new round of value growth cycle. From the initial exploration of License-out to the deep layout of global multi-center clinical trials, and the commercial breakthrough of cutting-edge technologies such as AI-driven R&D paradigms revolution, the industry is breaking through the red ocean of homogeneous competition and constructing a new ecosystem for differentiated development.

New Investment Summit Forum in Life Sciences (Parallel Session) —— Medical Devices

August 28th, all day

Cross-border symbiosis reshapes a new industrial ecosystem

In today's era of accelerating integration of global medical technology, the medical device industry is facing unprecedented transformation opportunities. From single hardware manufacturing to the construction of an ecosystem of "products + services + data," from regional market competition to the reconstruction of the global value chain, innovation boundaries are being continuously broken. The cross-integration of technologies in multiple fields such as AI and new materials is giving rise to a new generation of intelligent diagnosis and treatment solutions, injecting new momentum into the industry's development.

3,Forum Agenda

Parallel Session of the New Investment Summit Forum in Life Sciences - Medical Special Session (August 28)

9:00 - 9:30	Sign-in
9:30 - 9:35	Opening Remarks fatteningPartner and Managing Director, Frost & Sullivan Greater China
9:35 - 9:50	Guest Speech Professor Wang YuPresident of the China Foundation for the Prevention and Control of Hepatitis
9:50 - 10:15	Keynote 1: The Future of Healthcare: Innovation, Investment, and Global Collaboration - Unlocking China's Potential Rhenu BhullerAdvisory Board Member - Invest Melbourne, City of Melbourne
10:15 - 10:40	Keynote 2: Breaking Boundaries in the International Market: The Innovative Collaborative Approach between Multinational Pharmaceutical Companies and Chinese Local Pharmaceutical Enterprises Multinational pharmaceutical company
10:40 - 10:55	tea break
10:55 - 11:20	Keynote 3: Leveraging Product Power and Strategic Construction Before and After Listing Amid Industry Transformation Waves Yang DajunChairman and CEO of Yasheng Medicine Group
11:20 - 12:30	Roundtable Discussion 1: Transcending Cycles: The Capital Lifecycle Management Approach of Biopharmaceutical Companies Host:Huang Xinyi Vice President of Investment Banking at CICC Panelists:Li LihuaVP of R&D Management at Biotrium Pharmaceutical Group Zhang JingCFO of MindTree Pharma Liu YimingPartner-in-Chief, Shanghai Office of KLL Law Firm Wan YongChairman of SULLIVAN TELE-TREND CLOUD TECHNOLOGY, Chief Executive Officer of TradeGo & Frost & Sullivan Advisor
12:30 - 13:30	Lunch
13:30 - 13:55	Keynote 4:Accelerate the clinical transformation efficiency of first-in-class innovative drugs Small molecule targeted drug R&D enterprise
13:55 - 14:20	Lecture 5: Exploration and Practice of Mitochondrial Medicine in Longevity Medicine Lin ZirongExecutive President of Canoo Biotech
14:20 - 14:25	Release Ceremony of the 'White Paper on the Current Situation and Development Trends of the Mitochondrial Medicine Industry in 2025' Zhang Chenyang Consulting Director, Healthcare Business Unit, Frost & Sullivan Greater China
14:25 - 14:50	Keynote 6: Analysis of New Generation TCE Technology Prospects Filial piety and good fortuneChairman and CEO of Shimai Pharmaceutical
14:50 - 14:55	Blue Book on the Current Situation and Development Trends of Antibody Drugs Industry 2025 is Released Li QianExecutive Director, Healthcare Business Unit, Frost & Sullivan Greater China
14:55 - 15:10	tea break
15:10 - 15:35	Keynote 7:RDC industry opportunities and development JinglanSenior Director of Business Development at Tongrui Biotechnology
15:35 - 16:00	Keynote 8: Cell Therapy Enters the Deep Waters of Industry: Technological Upgrades and Commercialization Challenges Proceed Hand in Hand Chen XingrongFosun Karry CEO
16:00 - 16:25	Keynote 9: Biotech Innovation Paradigms in the AI4S Era: A Path from Algorithm to Experiment Integration AI Intelligent Automation Enterprise
16:25 - 17:35	Roundtable Discussion 2: Biomedicine under Globalization: Opportunities, Challenges and Strategies Host:Liu XiaolanCITIC Securities Managing Director Panelists:Zhou GuoyingFounder & CEO of Yino Wei Medicine Wei JunCo-founder and CEO of Ruijian Medicine Jinhua JunCEO and CTO of Jun Sai Biology Wang Hongyuan CEO of Huali Lejian Ni DongyaoSenior Vice President, Xibiman Biosciences
17:35 - 17:40	Host's Closing Remarks

Scan the QR code to register now

Parallel Session of the New Investment Summit Forum in Life Sciences - Medical Devices (August 28)

9:00 - 9:30	Sign-in
9:30 - 9:35	Opening Remarks Wang ChenhuiManaging Partner and President of Frost & Sullivan Greater China Region
9:35 - 9:50	Guest Speech Cai JiangnanFounder and Executive Chairman of Shanghai Chuangqi Health Development Research Institute
9:50 - 10:15	Keynote 1: Analysis of Philips' Innovation Ecosystem Building Wen YueqiangGeneral Manager, Cardiac Care Business Unit, Philips (China) Investment Co., Ltd.
10:15 - 10:40	Keynote 2: Embracing Centralized Procurement - The Catalyst Effect ignites the commercialization engine under the new centralized procurement landscape ChehaiboChairman of CoreLogic Healthcare Technology
10:40 - 10:55	tea break
10:55 - 11:20	Keynote 3: Analysis of New Investment Ideas in Medical Devices for 2025 Sun XiaoluFounder and Managing Partner of Binlinxing Venture Capital
11:20 - 12:20	Innovation-driven and Ecological Collaboration: The Breakthrough Path for the High-quality Development of Medical Devices in China Moderator:Cai LintingVice President, Morgan Stanley Panelists:Yang HeCEO of Weima Medical Zheng Hongzhe President of Yuwell Medical's Strategic Business Unit Xing ZhikaiDirector of Engineering Technology Center, Shanghai MicroPort Medical Technology (Group) Co., Ltd.
12:20 - 13:20	Lunch
13:20 - 13:45	Keynote 4Innovation and breakthroughs in innovative biomedical materials in the field of high-end medical implant devices Guo GuangxuChairman and CEO of EyeMed Medical
13:45 - 14:10	Keynote 5:Product iteration and new competition logic of cardiovascular devices Cardiovascular device R&D enterprise
14:10 - 14:15	Release Ceremony of the Blue Book in the Medical Device Field Hao ShuaiConsulting Director, Healthcare Business Unit, Frost & Sullivan Greater China
14:15 - 14:30	tea break
14:30 - 14:55	Keynote 6:The Innovative Butterfly Transformation of Minimally Invasive Interventional Cryotherapy Zhu JunGeneral Manager of Kangfeng Biology
14:55 - 15:20	Keynote 7:Technological Innovation and Development of Recombinant Humanized Triple Helix Collagen and Its Medical Aesthetic Applications Zhang ChunliHengyi Biology CTO
15:20 - 15:25	Release Ceremony of the "Blue Book on the Current Situation and Future Development of Medical Beauty Injection Products Industry in 2025" Zhao YidiConsulting Director, Healthcare Business Unit, Frost & Sullivan Greater China
15:25 - 15:50	Keynote 8: Overseas Commercialization Practice of Minimally Invasive Surgical Robots —— Ambitious Plans for the Future Liu YuExecutive Director, Executive Vice President, and Chief Commercial Officer of Shanghai MicroPort Medical Robotics (Group) Co., Ltd.
15:50 - 16:15	Keynote 9: Technological Breakthroughs in Core Components of Medical Equipment and the Improvement of Domestic Supply Chains Large-scale R&D enterprise of core components for medical equipment
16:15 - 17:15	Roundtable Discussion 2: From Followership to Leadership: The Road to Innovation and Market Reconfiguration in China's Medical Devices Moderator:Chen Qiqiang CITIC Securities Investment Banking Business Management Committee, Vice President Panelists:Liu MaiChairman of Yongxin Medical Dinglin & Aike Medical's Chief Financial Officer Ye YingHannover Medical Board Secretary ding ding dingBrand and Investor Relations Manager at Northcore Technology
17:15 - 17:20	Host's Closing Remarks

The 2025 Frost & Sullivan New Investment Conference —— New Investment Summit in Life Sciences is about to set sail!

Scan the QR code to register for the event now

4,GIL Awards Announcement

The Frost & Sullivan Growth, Innovation & Leadership Best Practices (referred to as the 'GIL Awards') aim to recognize outstanding enterprises that have made significant contributions and achieved leadership positions in various industries. After nearly 30 years of development globally, the authority and fairness of the awards are widely recognized by the investment and financial communities, as well as within the industry. To date, the awards have recognized more than 5,000 outstanding enterprises worldwide.

The year 2025 marks the 64th anniversary of Frost & Sullivan's global establishment. Frost & Sullivan China will continue to track and research a large number of successful entrepreneurial and investment cases in high-tech industries and strategic emerging industries within 2025. They will conduct objective and in-depth analysis to comprehensively evaluate the innovation capabilities, business models, founding teams, technical capabilities, and development prospects of the participating enterprises. Together with a professional judging committee, they will ultimately select several outstanding biotech leading enterprises. The award results for the GIL Awards for 2025 will be grandly announced during the award ceremony and VIP reception of the Frost & Sullivan Global Growth, Innovation and Leadership Awards 2025 at this conference.

Highlights from the 2024 Frost & Sullivan Growth, Innovation and Leadership Awards Ceremony and VIP Reception

5,Blue Book Release

At the 2025 Frost & Sullivan New Investment Conference, at the Life Sciences New Investment Summit Forum, Frost & Sullivan will release to the global community:

Blue Book on the Current Situation and Development Trends of Antibody Drugs Industry in 2025, Chinese and English versions

With continuous innovation in the global biopharmaceutical industry, antibody drugs are continuously expanding their application boundaries in areas such as oncology, autoimmune diseases, and rare diseases due to their advantages such as high specificity, high affinity, and low immunogenicity.

The successive emergence of new configurations such as bispecific antibodies, antibody-drug conjugates (ADCs), and nanobodies has enriched clinical treatment options and driven a profound reshaping of the industry competition landscape. As an important emerging force in biopharmaceutical innovation in China, driven by favorable policies, capital support, and technological innovation, the antibody industry has achieved a rapid leap from start-up and catch-up to independent innovation. Against this backdrop, it is of great significance for understanding industry development that Frost & Sullivan systematically sorts out the technological evolution, market size, industry pattern, and development trends of the global and Chinese antibody industries.

[Participating in the Blue Book of Cooperation]

Scan the QR code below to get in touch with us!

Blue Book on the Current Development Status and Future Trends of Medical Beauty Injection Products in 2025, Chinese and English Edition

Frost & Sullivan successfully released the 'Blue Book on the Current Development Status and Future Trends of the Medical Beauty Injection Product Industry' in 2024, which has attracted widespread attention within the industry. The article has received over 100,000 views and more than 10,000 downloads per copy. It has successfully linked with over 4,500 investment and financing institutions, effectively assisting in connecting upstream and downstream companies and investment institutions in the medical beauty sector, helping enterprises enhance their influence and gain greater attention in the capital market. To continuously track industry hotspots.

Frost & Sullivan will release the 'Blue Book on the Current Development and Future Trends of Medical Beauty Injection Products in China 2025' at the parallel session of the New Investment Summit on Life Sciences —— Devices. The report will delve into the latest developments, market status quo, and future trends of popular and emerging products in China's medical beauty injection product industry, uncovering the industry's tremendous potential. It will also analyze the driving factors behind market development, aiming to provide valuable references for corporate decision-makers, policymakers, investors, and consumers within the industry. At the same time, it will offer a platform for companies to showcase their technical strength, market strategies, and business advantages, promoting knowledge sharing and best practice exchanges, and jointly stimulating the innovative vitality and continuous progress of China's medical beauty injection product industry. In addition, the English version of the Blue Book will also be published in mainstream global media, further enhancing the company's global visibility and influence and supporting the company's internationalization strategy.

The 'White Paper on the Current Situation and Development Trends of the Mitochondrial Medicine Industry in 2025' written by Frost & Sullivan focuses on the field of mitochondrial medicine, delving into its core development context. It comprehensively analyzes the current industry situation, including key elements such as technological research and development progress, clinical application scope, market size, and growth trends. At the same time, it accurately predicts future development directions, providing comprehensive and in-depth strategic guidance for corporate decision-makers, policymakers, and investors in the mitochondrial medicine industry. This white paper aims to help all parties in the market gain an in-depth understanding of the mitochondrial medicine industry environment, clarify the competitive landscape, explore emerging market opportunities, and promote resource integration and collaborative innovation. It is hoped that through this platform, industry colleagues can join hands to draw a new blueprint for the development of the mitochondrial medicine industry and jointly push the industry towards a more specialized, precise, and cutting-edge future.

6,Conference registration channel